SIREN : 410219364
RX FRANCE is a French company founded 29 years ago, specialized in the sector Organisation de foires, salons professionnels et congrès. Based in PUTEAUX (92800), this company of category ETI shows in 2024 a revenue of 238.7 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2022 | 2021 | 2020 | 2019 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 238 713 769 € | 208 252 993 € | 113 705 698 € | 10 696 466 € | 119 817 263 € | 119 954 121 € | 160 948 406 € |
| Net income | 40 871 638 € | 24 751 933 € | -47 718 116 € | -48 172 783 € | 14 861 888 € | 8 449 285 € | 22 422 990 € |
| EBITDA | 64 938 999 € | 25 860 447 € | -16 479 998 € | -5 094 283 € | 52 501 058 € | 52 867 680 € | 74 103 720 € |
| Net margin | 17.1% | 11.9% | -42.0% | -450.4% | 12.4% | 7.0% | 13.9% |
In 2024, RX FRANCE achieves revenue of 238.7 M€. Over the period 2016-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +5.1%. Vs 2022, growth of +15% (208.3 M€ -> 238.7 M€). After deducting consumption (0 €), gross margin stands at 238.7 M€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 64.9 M€, representing 27.2% of revenue. Positive scissor effect: EBITDA margin improves by +14.8 pts, sign of improved operational efficiency. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 40.9 M€, i.e. 17.1% of revenue. This profit can be retained or distributed to shareholders.
238 713 769 €
238 713 769 €
64 938 999 €
41 459 389 €
40 871 638 €
27.2%
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 26%. The balance between equity and debt is satisfactory. Cash flow represents 18.3% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
0.007%
25.717%
18.336%
0.0
3.0%
In 2024, the debt ratio of RX FRANCE (0.01) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
In 2024, the financial autonomy of RX FRANCE (25.7%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of RX FRANCE (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 134.02. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 1.0x. Coverage is limited: any activity downturn would jeopardize interest payments.
134.016
1.038
In 2024, the liquidity ratio of RX FRANCE (134.02) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2024, the interest coverage of RX FRANCE (1.0x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 95 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 229 days. Excellent situation: suppliers finance 134 days of the operating cycle (retail model). Overall, WCR represents 157 days of revenue, i.e. 104.2 M€ to permanently finance. Over 2016-2024, WCR increased by +82%, requiring additional financing.
104 193 786 €
95 j
229 j
0 j
157 j
Based on 63 transactions of similar company sales
(all years),
the value of RX FRANCE is estimated at
113 919 953 €
(range 51 830 545€ - 341 105 388€).
With an EBITDA of 64 938 999€, the sector multiple of 1.6x is applied.
The price/revenue ratio is 0.68x
(in line with sector norms).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 63 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare RX FRANCE with other companies in the same sector:
Voir toutes les statistiques du secteur Organisation de foires, salons professionnels et congrès
The revenue of RX FRANCE in 2024 is 238.7 M€.
Yes, RX FRANCE generated a net profit of 40.9 M€ in 2024.
The headquarters of RX FRANCE is located in PUTEAUX (92800), in the department Hauts-de-Seine.
The tax return of RX FRANCE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
RX FRANCE operates in the sector Organisation de foires, salons professionnels et congrès (NAF code 82.30Z). See the 'Sector positioning' section above to compare the company with its competitors.